Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in normal tissues: insights from a new p21 reporter mouse

Michael McMahon, Tania G. Frangova, Colin J. Henderson, C. Roland Wolf (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    7 Citations (Scopus)
    172 Downloads (Pure)

    Abstract

    Many drugs targeting the DNA damage response are being developed as anti-cancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in progress or planned. However, concerns remain about the potential of such treatments to increase toxicity to normal tissues. In order to address this issue, a novel reporter mouse line was created through the simultaneous incorporation of multiple reporters, b-galactosidase and firefly luciferase, into the DNA damage-inducible p21 (CDKN1A) locus. The data demonstrate that in situ b-galactosidase staining facilitates high fidelity mapping of p21 expression across multiple organs and tissues at single-cell resolution, whereas the luciferase reporter permits non-invasive bioluminescent imaging of p21 expression. This model was used to determine the capacity of a number of DNA damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues. In addition, the PARP inhibitor olaparib was examined alone or in combination with IR as well as cisplatin. A single exposure to olaparib alone caused DNA damage to cells in the mucosal layer lining mouse large intestine. It also exacerbated DNA damage induced in this organ and the kidney by co-administered IR. These studies suggest that olaparib has carcinogenic potential and illustrate the power of this new model to evaluate the safety of new therapeutic regimens involving combination therapies.

    IMPLICATIONS: Olaparib causes DNA damage to normal tissues and might be a carcinogen.

    Original languageEnglish
    Pages (from-to)1195-1203
    Number of pages9
    JournalMolecular Cancer Research
    Volume14
    Issue number12
    Early online date7 Sep 2016
    DOIs
    Publication statusPublished - Dec 2016

    Fingerprint

    Ionizing Radiation
    DNA Damage
    Galactosidases
    Cisplatin
    Firefly Luciferases
    Large Intestine
    Cytotoxins
    Etoposide
    Therapeutics
    Drug Delivery Systems
    Luciferases
    Carcinogens
    olaparib
    Clinical Trials
    Staining and Labeling
    Kidney
    Safety
    DNA
    Neoplasms

    Keywords

    • DNA damage
    • CDKN1A
    • olaparib
    • PARP inhibitors
    • anticancer drugs

    Cite this

    @article{84837c4071ab47599318ace10de39877,
    title = "Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in normal tissues: insights from a new p21 reporter mouse",
    abstract = "Many drugs targeting the DNA damage response are being developed as anti-cancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in progress or planned. However, concerns remain about the potential of such treatments to increase toxicity to normal tissues. In order to address this issue, a novel reporter mouse line was created through the simultaneous incorporation of multiple reporters, b-galactosidase and firefly luciferase, into the DNA damage-inducible p21 (CDKN1A) locus. The data demonstrate that in situ b-galactosidase staining facilitates high fidelity mapping of p21 expression across multiple organs and tissues at single-cell resolution, whereas the luciferase reporter permits non-invasive bioluminescent imaging of p21 expression. This model was used to determine the capacity of a number of DNA damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues. In addition, the PARP inhibitor olaparib was examined alone or in combination with IR as well as cisplatin. A single exposure to olaparib alone caused DNA damage to cells in the mucosal layer lining mouse large intestine. It also exacerbated DNA damage induced in this organ and the kidney by co-administered IR. These studies suggest that olaparib has carcinogenic potential and illustrate the power of this new model to evaluate the safety of new therapeutic regimens involving combination therapies.IMPLICATIONS: Olaparib causes DNA damage to normal tissues and might be a carcinogen.",
    keywords = "DNA damage, CDKN1A, olaparib, PARP inhibitors, anticancer drugs",
    author = "Michael McMahon and Frangova, {Tania G.} and Henderson, {Colin J.} and Wolf, {C. Roland}",
    note = "Copyright {copyright, serif}2016, American Association for Cancer Research.",
    year = "2016",
    month = "12",
    doi = "10.1158/1541-7786.MCR-16-0108",
    language = "English",
    volume = "14",
    pages = "1195--1203",
    journal = "Molecular Cancer Research",
    issn = "1541-7786",
    publisher = "American Association for Cancer Research",
    number = "12",

    }

    TY - JOUR

    T1 - Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in normal tissues

    T2 - insights from a new p21 reporter mouse

    AU - McMahon, Michael

    AU - Frangova, Tania G.

    AU - Henderson, Colin J.

    AU - Wolf, C. Roland

    N1 - Copyright {copyright, serif}2016, American Association for Cancer Research.

    PY - 2016/12

    Y1 - 2016/12

    N2 - Many drugs targeting the DNA damage response are being developed as anti-cancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in progress or planned. However, concerns remain about the potential of such treatments to increase toxicity to normal tissues. In order to address this issue, a novel reporter mouse line was created through the simultaneous incorporation of multiple reporters, b-galactosidase and firefly luciferase, into the DNA damage-inducible p21 (CDKN1A) locus. The data demonstrate that in situ b-galactosidase staining facilitates high fidelity mapping of p21 expression across multiple organs and tissues at single-cell resolution, whereas the luciferase reporter permits non-invasive bioluminescent imaging of p21 expression. This model was used to determine the capacity of a number of DNA damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues. In addition, the PARP inhibitor olaparib was examined alone or in combination with IR as well as cisplatin. A single exposure to olaparib alone caused DNA damage to cells in the mucosal layer lining mouse large intestine. It also exacerbated DNA damage induced in this organ and the kidney by co-administered IR. These studies suggest that olaparib has carcinogenic potential and illustrate the power of this new model to evaluate the safety of new therapeutic regimens involving combination therapies.IMPLICATIONS: Olaparib causes DNA damage to normal tissues and might be a carcinogen.

    AB - Many drugs targeting the DNA damage response are being developed as anti-cancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in progress or planned. However, concerns remain about the potential of such treatments to increase toxicity to normal tissues. In order to address this issue, a novel reporter mouse line was created through the simultaneous incorporation of multiple reporters, b-galactosidase and firefly luciferase, into the DNA damage-inducible p21 (CDKN1A) locus. The data demonstrate that in situ b-galactosidase staining facilitates high fidelity mapping of p21 expression across multiple organs and tissues at single-cell resolution, whereas the luciferase reporter permits non-invasive bioluminescent imaging of p21 expression. This model was used to determine the capacity of a number of DNA damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues. In addition, the PARP inhibitor olaparib was examined alone or in combination with IR as well as cisplatin. A single exposure to olaparib alone caused DNA damage to cells in the mucosal layer lining mouse large intestine. It also exacerbated DNA damage induced in this organ and the kidney by co-administered IR. These studies suggest that olaparib has carcinogenic potential and illustrate the power of this new model to evaluate the safety of new therapeutic regimens involving combination therapies.IMPLICATIONS: Olaparib causes DNA damage to normal tissues and might be a carcinogen.

    KW - DNA damage

    KW - CDKN1A

    KW - olaparib

    KW - PARP inhibitors

    KW - anticancer drugs

    U2 - 10.1158/1541-7786.MCR-16-0108

    DO - 10.1158/1541-7786.MCR-16-0108

    M3 - Article

    C2 - 27604276

    VL - 14

    SP - 1195

    EP - 1203

    JO - Molecular Cancer Research

    JF - Molecular Cancer Research

    SN - 1541-7786

    IS - 12

    ER -